Oral SERDS for HR+/HER2 Neg ESR1m MBC
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

Released: January 31, 2025

Expiration: July 30, 2025

Activity

Progress
1
Course Completed

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:

  • Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast cancer
  • Current guideline recommendations for when to pursue ESR1 mutation testing mutations in patients with HR-positive/HER2-negative advanced breast cancer
  • Choice and sequencing of next line of systemic therapy for ESR1-mutated advanced breast cancer based on tumor molecular alterations
  • Overview of class-related and unique adverse events with approved and emerging oral SERDS
  • Expert recommendations for the management of oral SERDs-related adverse events